Abacavir - myocardial infarction - Uppsala Monitoring Centre

Signal from Dr Emilio Sanz, Spain.Table 3. Case report summaries.Time interval(months)Proteaseinhibitor therapy Dechallenge Rechallenge Outcome1 15 X Recovered3 4 U4 11 X Recovered with sequelae5 1d X X U6 23 X U7 52d U8 45d X U9 16 Died10 X X U11 X U12 12 Recovered with sequelae13 X Recovered with sequelae14 8 X Recovered with sequelae15 X U16 2d X Died17 9 X U18 X U19 19d X X Recovered with sequelae21 15 X Recovered22 23 X Not recovered23 10 Died26 X U27 11 X U28 X Not recovered29 X U30 X U31 12 X U33 X U34 9 X UU: unknownd: daysReferences:1. DRUGDEX(R) Editorial Staff 02/2004. Several references pointed out to theassociated risks of protease inhibitors and MI. In particular see: Combinationantiretroviral therapy and the risk of myocardial infarction. The Data Collection onAdverse Events of Anti-HIV Drugs (DAD) Study Group. N Engl J Med 2003;349(21):1993-2003.2. No references to cardiovascular side effects on Martindale or PDR (2004)(Micromedex).WHO SIGNAL May 20055The Uppsala Monitoring Centre